HOSP 2006

Trial name or title	HOSP Study
Methods	Multicentre, prospective, randomized, open, 2 x 2 factorial design, blinded end point study. Participants were randomly assigned to a modest or strict blood pressure control group, and to an amlodipine or losartan group. The participants were to be followed up for 5 years
Participants	Men and women aged 40 to 79 years and clinical diagnosis of hypertension. Exclusion criteria included severe hypertension (treated with ≥3 antihypertensive drugs), people unable to change antihypertensive drugs to a calcium antagonist or an angiotensin antagonist, serious medical conditions and women who may become to be pregnant
Interventions	Standard (modest) target: Home SBP < 140 mmHg Intensive (strict) target: Home SBP < 130 mmHg
Outcomes	Primary outcome measures: Combined cardiovascular events. Secondary outcome measures: Total mortality, cardiovascular mortality, MI and new‐onset angina, stroke and TIA, kidney failure, aortic and peripheral artery diseases, left ventricular mass and function, urinary albumin and Kidney function
Starting date	April 2000
Contact information	Yuhei Kawano, MD, PhD, Division of Hypertension and Nephrology, National Cardiovascular Center, 5‐7‐1 Fujishirodai, Suita, Osaka 565‐8565, Japan. E‐mail: ykawano@hsp.ncvc.go.jp
Notes	We have tried to contact Dr Kawano to obtain information on the current situation of the trial